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Group	B	streptococcus	or	
GBS	(Streptococcus	agalactiae)
§ Since the 1970s, leading cause of life-threatening 
infections in newborns
§ Neonatal illness/death
§ Early & Late Onset Disease (EOD, LOD)
§ Long-term disabilities
§ GBS EOD
§ Before mid-1990s: 2-3/1000 live births
§ Today, prevention era : 0.2 - 1/1,000 live births 
§ Meningitis :  10 %
§ Mortality : 4 - 10 % (20-30% if premature)
§ GBS LOD




Also in developing low 
income countries
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Neonatal GBS EOD
Vertical transmission
§ Leading cause of life-threatening infections in newborns
§ Neonatal illness/death
§ Long-term disabilities
§ Vertical transmission during labor & birthing
GBS colonized mothers (*)
Colonized
newborns
60 - 40 % 40 - 60 %
Non-colonized
newborns
(*) : carriage 10-35% of pregnant women (transient, intermittent or chronic)
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§ Leading cause of life-threatening infections in newborns
§ Neonatal illness/death
§ Long-term disabilities
















2 - 4 %
Early onset disease
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Additional	Risk	Factors	
for	Early-Onset	GBS	Disease
§ Obstetric factors*: 
§ Prolonged rupture of 
membranes, 
§ Preterm delivery, 
§ Intrapartum fever
§ GBS bacteriuria
§ Previous infant with GBS disease*
§ Immunologic: 
§ Low specific IgG to GBS capsular 
polysaccharide
*: No difference in occurrence either in GBS Positive 
or Negative women, except intrapartum fever
Lorquet S., Melin P. & al. J Gynecol Obstet Biol Reprod 2005
Risk 
factors











Point of care testing of GBS, isn’t it obvious ? ECCMID 2018 3
ECCMID 2018 / GBS POCT / PM / CHULg 9
Colonized woman




> 4 hours before delivery
Highly effective in preventing GBS EOD (1st clinical trials in late 80s)
Challenge:





To mitigate transmission and reduce chance of invasive infection.
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POCT FOR GBS, 
ISN’T IT CLINICALLY OBVIOUS ?
Guidelines for prevention
Efficacy, concerns & drawbacks
Room for improvement
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 Impact	of	prevention	practices
 Early- and	Late-onset	GBS	Diseases,	U.S.
Incidence of early- and late-onset invasive group B streptococcal disease in 


















































department of health and human services
Centers for Disease Control and Prevention
Recommendations and Reports November 19, 2010 / Vol. 59 / No. RR-10
Morbidity and Mortality Weekly Report
www.cdc.gov/mmwr
Prevention of Perinatal Group B 
Streptococcal Disease
Revised Guidelines from CDC, 2010









No effect on GBS LOD
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European	strategies	
for	prevention	of	GBS	EOD
§ Intrapartum antibioprophylaxis recommended
§Screening-based strategy 
(issued by prof.societies; by public health authorities) 
§ Spain, 1998, 2003, revised 2012 
§ France, 2001, 2017 
§ Belgium, 2003, revised 2015 
§ Germany, 1996, revised 2008 
§ Switzerland, 2007 
§Risk-based strategy
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Antenatal	GBS	culture-based	
screening
Goal of GBS screening
To predict GBS vaginal (rectal) colonization at the time 
of delivery
§Crucial factors influencing accuracy
§ Swabbed anatomic sites (distal vagina & rectum)
§ Timing of sampling (35-37 wks)




§ + selective enrichment broth further sub-cultured (LIM)
§ Media
§ Blood agar (b-hemolysin), Granada & chromogenic agars
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From direct	plating on	blood agar
Evolution	of	culture	methods
Use of differential agar media (>> CNA Blood agar)
Recommended by some European guidelines (+ CDC 2010)










Use of selective enrichment broth
§ To maximize the isolation of GBS
§ To avoid overgrowth of other organisms
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Antenatal	GBS	culture-based	screening
Goal of GBS screening
To predict GBS vaginal (rectal) colonization at the 
time of delivery
§Critical factors influencing accuracy
§ Swabbed anatomic sites
§ Timing of sampling (35-37 wks)





§Nucleic Acid Amplification Test (NAAT) 





A loop mediated 
isothermal 
amplification (LAMP) 






BD MAX™ GBS 
assay
Fully-automated, real-
time PCR method.  
(High throughput ) 
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About	analytically reliable diagnostic	devices/systems for
Real-time	NAAT	GBS	LB	assays
Impact on diagnostics ?




Clinical significance of  
results?
Cost-benefits ?
When to use which techniques? 
For selected patients? 
Alone or combined with conventional methods?  
Will results be able to change  behaviour?
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About	analytically reliable diagnostic	devices/systems for
Real-time	NAAT	GBS	LB	assays
Impact on diagnostics ?
Could improve it in some labs !
Impact on patient 
management, care ?
Could be improved for some
pregnant women and neonates
Impact on Turn-around-
time?
Up to 48h shorter, but not 
essential as antenatal. 
Elegant, streamlined solution.
Clinical significance of  
results?






resources, quality of 
culture procedures, 
etc.
When to use which techniques? 
For selected patients? 
Alone or combined with conventional methods?  
Will results be able to change  behaviour?
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Antenatal	GBS	culture-based	screening
Goal of GBS screening
To predict GBS vaginal (rectal) colonization at the 
time of delivery
§Crucial factors influencing accuracy
§ Swabbed anatomic sites






§Nucleic Acid Amplification Test (NAAT) 
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Concerns about	potential adverse	/	
unintended events related to	IAP
§ Allergies  
§ Anaphylaxis occurs but extremely rare
§ Changes in incidence or resistance of other pathogens causing
EOD
§ Data are complex …
§ BUT Most studies: stable rates of « other » sepsis
§ Impact on development of the neonatal intestinal microbiome. 
§ Changes in GBS antimicrobial resistance profile
§ Increase of resistance to clindamycin (10 to 40% in Europe, USA; up to 70% 
in Asia)
§ Very very rare decrease of susceptibility to penicillin







§ Some missed opportunities
§ Results not available
§ False Negative screening
§ Change of GBS status
§ Colonization dynamics
§ Lack of viability
§ Transport conditions, 
antibiotherapy, personal 
hygiene 




§ False Positive screening
§ Change of GBS status
§ Colonization dynamics
§ A lot of missed opportunities
§ Lack of adhesion
§ Incomplete assessment of 
risks
§ Up to 65% of cases not 
associated to RF
§ Half up to 80% of women 





 of true +
Up to 30 % of antenatal positive
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Towards a	« European	Consensus »
Decision taken by a European working party 
(Neonatologists, obstetricians, microbiologists) 
including countries with screening-based IAP, with risk-based IAP 
strategies or no strategy at all (June 2013, Florence, Italy)
Main recommendations 
§ Universal screening at time of delivery (when appropriate POCT available)
§ POCT with high PPV and NPV
§ Real time PCR or other methods
§ TAT < 1 hour
§ IAP for all GBS positive pregnant women 
§ documented by intrapartum testing (or late pregnancy test if 
performed)
§ Late pregnancy antenatal screening in known penicillin allergic 
women 
§ Determination of clindamycin susceptibility if GBS positive screening
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q Inclusion of women without antenatal screening / care
q Identification of women with change of GBS status after 35-37 wks
gestation




IAP addressed to right target
§ Reduction of inappropriate / unnecessary IAP
§ Broader coverage of « at GBS risk women » 
Improvement of prevention 
q No antimicrobial susceptibility results
(à in case of penicillin allergy, antenatal screening)
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Intrapartum	screening
Expected	advantages	&	drawback
Improvement of prevention 
GBS POCT 
performed on vaginal specimen 
at admission for delivery
= 
Valuable alternative method for accurate identification 
of GBS colonized women at delivery
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POCT FOR GBS, 
IS IT TECHNICALLY OBVIOUS ?
Old or new tools to detect GBS ?
Response to a 30 year “dream” but also an obvious need.
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XXIst century,	Medical	evolutionary	background
Factors impacting on development and daily 
practice of microbiology
§ Medical environment
§ Increasing emphasis on evidence-based medicine 
and adherence to guidelines
§ Economic environment
§ Cost-effective use of available resources
§ Reimbursement system, regulation 
§ Evolution of technological background
§ Exponential progress: molecular biology and robots
§ New platforms from “sample-in / result-out”
§ Continuation of advance to accelerate in the near future
§ Quality assurance, traceability, LIS                
§ Global increase of antimicrobial resistance 













30-45 minutes, 24 hrs/7 d, robust
Benitz et al. 1999, Pediatrics, Vol 183 (6)
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§ Fully automated and robust test & platform
§ Sensitivity >90%, specificity>95%, negative and 
positive predictive values
§ Turn Around Time (TAT) < 1 hour
§ Internal QC / embedded process control / control for 
presence of specimen on board
§ Workflow; very limited hands-on-time
§ Easyness to perform and to interprete (clear-cut result)
§ Low rate of invalid / error results
§ Availability 24h/7d
§ Limited training (high turnover among nurses/midwives)
§ Cost-effective 
§ Traceability, connectivity to electronic medical files
§ Small footprint, low noise level
§ Minimized waste 
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INTRAPARTUM SCREENING 
FOR GBS
A POCT in the delivery room
Xpert® GBS Assay,
Cepheid
GenePOCTM GBS DS Assay,
GenePOC
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Xpert® GBS for intrapartum screening
(selected paper amongst many others)
Diagnostic Accuracy of a Rapid Real-Time Polymerase Chain 
Reaction Assay for Universal Intrapartum Group B Streptococcus 
Screening 
Najoua El Helali, Jean-Claude Nguyen, Aïcha Ly, Yves Giovangrandi and 
Ludovic Trinquart  
Clinical Infectious Diseases 2009;49:417–23
§ 968 Pregnant women
§ Intrapartum Xpert GBS, Cepheid (performed in lab)




§ PPV 97.8% PPV 58.3%
§ NPV 99.7% NPV 92.1%




Study in CHU Liège / UZ Antwerp, Belgium (900 patients), 2014-
2015
1. To assess the practical aspects and analytical 
performances
§ Tests performed by midwives
§ Evolving team of +/- 50 midwives /hospital
§ For screening all women at onset of labor
2. To evaluate the cost-effectiveness of the 
intrapartum screening strategy
à To consolidate the proposal of the European 
Expert Group
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Xpert® GBS	results (Liege,	2014)
Intrapartum (IP)	culture	as	gold	standard
Pre-study Study Revision Following	period
08.04			 26.05			 11.08				 10.09	















Specificity 98.9% 100% 98.5% 97.6%
PPV 91.7% 100% 93.3% 87.5%
NPV 96.7% 91.7% 98.5% 87.2%
Error +	Invalid results 3% - 11%		
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Xpert® GBS	results (Liege,	2014)
Intrapartum (IP)	culture	as	gold	standard
Pre-study Study Revision Following	period



















Specificity 98.9% 100% 98.5% 97.6%
PPV 91.7% 100% 93.3% 87.5%
NPV 96.7% 91.7% 98.5% 87.2%
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Key	message	
Xpert® GBS POCT in the delivery room
§ High specificity but varying sensitivities !
§ Some invalid or error results
§ Time, cost to retest ???
§ Some expected improvements to secure the result  AND the 
patient management (specimen control)
§ Mucus interference
§ Higher Ct when test perform immediately after collection: better 
results a few hours later  
Commutability from lab to POC:
Not always an unconditional success story !
à Clinical validation of GBS POCT:
crucial to be performed on site,  by midwives and on fresh
specimens
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INTRAPARTUM SCREENING 
FOR GBS
A POCT in the delivery room
GenePOCTM GBS DS test, CE-marked, 2017
& the revogeneTM instrument, CE-marked & FDA cleared
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GenePOCTM GBS DS test for 
intrapartum screening
§ Real Time PCR on revogeneTM instrument
§ Detection of a cfb gene sequence specific of the GBS genome
§ On vaginal or vagino/rectal swab
§ Fully automated
§ Easy to use : 3 steps in 1 min 
§ Result in 70 minutes
§ Single-use microfluidic cartridges
§ Testing 1 up to 8 samples in one run
§ Embedded process control to monitor sample processing conditions
§ internal control  to monitor PCR conditions and the absence of reaction inhibition
GenePOCTM GBS DS Assay, validation by the Belgian NRC GBS
§ Currently tested in parallel with reference culture
§ Results: so far so good, evaluation still ongoing 
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GenePOCTM GBS DS test 
for intrapartum screening
Clinical performances characteristics of the GBS DS Assay in 
comparison to reference method





Positive 107 31B 138
Negative 4A 277 281
Total 111 308 419




A: GBS DNA detected in ½ false negative specimens tested using a second NAAT method











Intrapartum group B Streptococcus (GBS) 
detection by point-of-care real-time PCR 
testing (POCT)
Lutz Von Müller*, Germany
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CONCLUSION
Take home messages
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Summary
Neonatal GBS diseases & prevention 
§ GBS still a perinatal threat
§ EOD and LOD, a public health concern
§ Immunoprophylaxis , highly desirable but not 
yet available 
§ IAP efficient for prevention of EOD
§ Up to 80% reduction of EOD
§ Best strategy still a matter of debate
§ Antenatal screening >> risk factors   ??
§ IAP not widely recommended
§ Towards European consensus 2014
§ Universal screening, intrapartum when 
appropriate GBS POCT available
43ECCMID 2018 / GBS POCT / PM / CHULg
Summary
Intrapartum GBS POCT
§ Clinically OBVIOUS to reduce 
§ Missed opportunities of IAP
§ Unnecessary IAP
§ Inappropriate management of newborn
§ Clinically OBVIOUS
§ To better address the right target for IAP
§ But no AST result for penicillin allergic woman
§ A lot of papers relating the superiority of 
intrapartum GBS POCT–based IAP (Xpert® GBS)
§ Which “reference method” ?
§ Testing in lab versus on delivery site ?
§ Room for technical improvement ?
§ Hope in the new GenePOCTM GBS DS test 
& coming others still in the pipeline of development
